These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222 [TBL] [Abstract][Full Text] [Related]
46. Second-line systemic therapy for metastatic colorectal cancer. Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439 [TBL] [Abstract][Full Text] [Related]
47. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Khattak MA; Martin H; Davidson A; Phillips M Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296 [TBL] [Abstract][Full Text] [Related]
48. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study. Liang YH; Chen KH; Shao YY Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970 [TBL] [Abstract][Full Text] [Related]
49. [Target Therapy in Unresectable or Metastatic Colorectal Cancer]. Kim JH; Park SJ Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473 [TBL] [Abstract][Full Text] [Related]
51. [The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response]. Nemecek R; Vyzula R Klin Onkol; 2011; 24(6):465-9. PubMed ID: 22257237 [TBL] [Abstract][Full Text] [Related]
52. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. Weinberg BA; Hartley ML; Salem ME Oncology (Williston Park); 2017 Jul; 31(7):539-48. PubMed ID: 28712098 [TBL] [Abstract][Full Text] [Related]
53. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Grothey A; Fakih M; Tabernero J Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264 [TBL] [Abstract][Full Text] [Related]
54. New oxaliplatin-based combinations in the treatment of colorectal cancer. Cassidy J; Hochster H Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555 [TBL] [Abstract][Full Text] [Related]
55. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study. Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Lan YT; Lin CC; Yen CC; Tzeng CH; Teng HW J Cancer Res Clin Oncol; 2014 Nov; 140(11):1927-36. PubMed ID: 24934725 [TBL] [Abstract][Full Text] [Related]
57. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107 [TBL] [Abstract][Full Text] [Related]
58. Cetuximab in the treatment of patients with colorectal cancer. Garrett CR; Eng C Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708 [TBL] [Abstract][Full Text] [Related]
59. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478 [TBL] [Abstract][Full Text] [Related]
60. Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months. Hayashi K; Mitani S; Taniguchi H; Yasui H; Muro K; Mori K; Gotoda T; Yamazaki K Oncology; 2019; 96(3):132-139. PubMed ID: 30359979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]